Risk factors for intestinal colonization with vancomycin resistant enterococci’ A prospective study in a level III pediatric intensive care unit

Introduction

After the first report of vancomycin-resistant enterococci (VRE) was published from the UK and France in 1986, it has emerged as one of the major nosocomial pathogens across the globe.[1] Long-term stay in the hospitals may result in VRE colonization in the gut thus creating reservoirs of infection. Transmission of VRE from patient to patient occurs through hands of health-care workers and through contaminated fomites in the environment.[2] VRE colonization increases the risk of developing infection up to 5–10 fold.[3]

Enterococcus faecalis and Enterococcus faecium contribute to 80%–90% of all enterococcal infections such as bloodstream infection, endocarditis, meningitis, urinary tract infection, and wound infection.[4] Multidrug resistance, increased rate of gut colonization, use of broad-spectrum antibiotics, and invasive devices have been implicated in the emergence of VRE.[5] VRE bacteremia usually results in increased mortality rate and treatment cost when compared to bacteremia caused by vancomycin-sensitive enterococci.[67]

VRE colonization is a major burden in intensive care units (ICU's) of large tertiary care hospitals. The higher antibiotic pressure in the ICU's contributes to the increased rate of VRE colonization. Once patients get colonized with VRE, it may persist from 7 weeks to 3 years, which may lead to a variety of infections in ICU patients.[8] The risk factors, namely, prolonged hospitalization, immunosuppression, low birth weight, younger age group, and prolonged antibiotic consumption of vancomycin, teicoplanin, amikacin, and ceftazidime were found to be associated with VRE colonization in pediatric and newborn ICUs and also in children's hospitals.[59101112131415]

There are limited reports of VRE colonization particularly from pediatric ICU (PICU) across the globe with rates ranging from 0% to 66%.[2591617181920212223] A study from our neighboring country Pakistan (Southeast Asia) reported a VRE colonization in PICU of 10.7%.[5] At the time of undertaking this study, to the best of our knowledge, no reports were available from India on VRE colonization in PICU's. The main objectives of this study were to determine the rate of VRE colonization in patients admitted to PICU and to assess the risk factors associated with it.

Materials and Methods

Results

Out of 1290 patients admitted in PICU during the study period, 198 were screened for VRE. The detailed flow chart is mentioned in Figure 1.

Close

Figure 1

Flow chart of study

Export to PPT

The rectal swabs were collected from 198 patients admitted to PICU, out of which 37 (18.6%) yielded VRE. Of the VRE isolates, 75.6% were E. faecium and 24.4% were E. faecalis. The MIC values for both vancomycin and teicoplanin ranged from 64 to ≥256 for all the VRE isolates. Vancomycin resistance was always associated with teicoplanin resistance indicating that these VRE isolates were vanA-phenotype. PCR also confirmed vanA gene in all the 37 VRE isolates and none of them were positive for vanB and vanC genes. Very high rates of resistance to other antibiotics were noted with disc diffusion method (89%, 82%, and 86% to ampicillin, high-level gentamicin, and tetracycline, respectively). No resistance was observed to linezolid.

Among the various risk factors assessed, none of the demographic features of the patients admitted to PICU were associated with VRE Colonization [Table 1]. The average patient stay in the PICU before sample collection was 3.5 days (standard deviation ±3.84). No statistically significant association was found with VRE colonization rate and duration of patient stay, history of (H/O) previous hospital stay, and H/O surgery or urinary catheterization in PICU. Among the various antibiotics, vancomycin consumption was the only risk factor found to be significantly associated with VRE colonization in patients admitted to PICU (P = 0.006) [Table 2]. The average duration of vancomycin consumption was 2.2 days among VRE colonizers and 1.9 days among noncolonizers before sample collection. Of the 37 colonized patients, one patient acquired bloodstream infection after 7 days of VRE colonization. On the other hand, none of the 161 noncolonized patients acquired VRE infection.

Table 1 Association of demographic features with vancomycin-resistant enterococci colonization among patients admitted to pediatric intensive care unit (n=198) (logistic regression analysis)

Table 2 Association of risk factors with vancomycin-resistant enterococci colonization among patients admitted to pediatric intensive care unit (n=198) (logistic regression analysis)

Discussion

This study was conducted to detect the rates of VRE colonization among the patients admitted to PICU in a larger tertiary care hospital in southern India. ICUs are the major pool of infections with amplifying antimicrobial resistance. The heavy antibiotic burden in the ICUs provide a favorable environment for the development of resistance.[28] In this study, the rate of gut colonization with VRE was found to be 18.6% among patients admitted to PICU. In a study by Yameen et al., 2013, from Pakistan, 10.7% of VRE colonization rate was reported from patients admitted to PICU.[5] Nateghian et al., 2014,[23] from Iran, reported a high incidence of VRE colonization (66%). The rate of VRE colonization (18.6%) in our study correlates with other studies conducted in pediatric hospitals.[3202122] However, these studies also included patients admitted to pediatric wards in addition to ICUs. A few studies that include NICU patients reported higher rates of VRE colonization ranging from 39% to 66%[2923] whereas in a study reported by Bakir Saygan et al.,2010[18] and Singh et al., 2005,[19] from NICU, lower rates of VRE colonization of 0% and 3.5%, respectively, were encountered.

A meta-analysis study comprising adult patients admitted to hospitals in the USA reported an average VRE colonization rate of 12.5% with a range of 0%–42%.[29] However, data obtained from all the ICU's, that is, neonatal, pediatrics, and adults, VRE colonization rate varies from 0% to 66%.[212223272829] By comparing all these studies, it is clear that there is no specific association between age of the patients and colonization rates. These dissimilarities in the colonization rates may be dependent on geographical variation, hospital infection control policies, differences in health-care personal practices, and methodologies followed for the detection of colonization.

Previous studies have reported the association of various risk factors for VRE colonization such as prolonged hospitalization, immunosuppression, younger age group, prolonged antibiotic consumption such as vancomycin, teicoplanin, amikacin, and ceftazidime, administration of antimicrobial therapy for the late onset of neonatal sepsis.[159101112131415] In this study, the consumption of vancomycin was the only risk factor significantly associated with the VRE colonization. In contrast, in a study from our center in adult patients admitted to MICU, we observed prior ceftriaxone administration to be a significant risk factor.[30]

All the VRE isolates in this study had higher MIC value ranging from 64 ≥256 mg/L to both vancomycin and teicoplanin. This result depicts that all the strains are vanA-phenotype, that is, high-level resistance to both vancomycin and teicoplanin. Although the VRE isolates from this study showed very high rates of resistance to other antibiotics (89%, 82%, and 86% to ampicillin, high-level gentamicin, and tetracycline, respectively), no resistance was observed against linezolid. A few studies reported the emergence of resistance to linezolid among VRE isolates from colonized patients.[31] Antibiotics such as linezolid, tigecycline, and daptomycin are the treatment of choice for VRE infections, and most of the studies showed 100% sensitivity to these higher antibiotics.[32]

van A and van B are more commonly found among VRE isolates followed by vanC.[33] We also looked for the presence of van genes, that is, vanA, vanB, vanC-1, vanC-2, and vanC-3. In our study, only vanA gene was detected in all the VRE isolates, and no vanB and vanC genes were detected. vanA phenotypes are resistant to both vancomycin and teicoplanin due to the presence of vanA gene whereas vanB phenotype is only resistant vancomycin and sensitive to teicoplanin and carry vanB genotype. There is a variation in the global distribution of the van phenotype and genotypes. The majority of the VRE reported from the USA and Israel is the vanA phenotype while in Australia vanB phenotype is predominant.[34] In an earlier study from our hospital, we had reported both vanA and vanB phenotypes isolated from various clinical samples although in that study VRE isolates from both ICU and non-ICU patients were included.[4]

Out of 37 colonized patients in PICU, one patient (2.6%) acquired a VRE bloodstream infection after 7 days of detection of VRE colonization, while none of the 161 noncolonized patients was infected. VRE bloodstream infection rate among colonized patients ranging from 0% to 45% have been reported in many other studies.[3] The VRE isolated from rectal swab and blood of the same patient was of the same species, that is, E. faecium and exhibited similar antimicrobial sensitivity pattern. Based on these findings, we came to the purely tentative conclusion that the same strain went on to cause the infection. However, molecular characterization such as pulsed-field gel electrophoresis and multilocus sequence typing would have given a clearer picture about clonal relatedness.

The increase in VRE colonization and infection may lead to the risk of developing vancomycin resistance in Staphylococcus aureus strains. The colonization of patients with VRE and methicillin-resistant S. aureus (MRSA) increases the risk of acquiring vancomycin resistance by MRSA through plasmid-mediated gene transfer.[34] Hospital infection control practices advisory committee published the first guidelines in 1994 for the control of VRE infection in the hospitals.[35]

Limitation of the study is that rectal swab was collected at a single point of time. Follow-up rectal swabs of initially noncolonized patients would have provided information on VRE acquisition rate during the stay. We did not include pediatric control group in non-ICU areas which could have revealed any differences in the rates of VRE colonization in different hospital areas.

Conclusion

VRE colonization rate is moderately high in PICU of our hospital with prior vancomycin usage the only significant risk factor. Routine surveillance and isolation of patients found to be VRE-colonized may not be feasible in tertiary care hospitals; however, educating health-care workers, promoting handwashing with antiseptic soaps or solutions, and antibiotic Stewardship policy may help in the reduction of vancomycin resistance and VRE colonization.